|
| Wednesday, 24 April 2019, 16:53 HKT/SGT | |
| |  | |
Source: Eisai | |
|
|
|
TOKYO, Apr 24, 2019 - (JCN Newswire) - Eisai Co., Ltd. has announced that the latest data on its dual orexin receptor antagonist lemborexant and its antiepileptic drug (AED) perampanel (product name: Fycompa) will be presented at the 2019 Annual American Academy of Neurology (AAN) Meeting to be held from May 4 to 10, 2019 in Philadelphia, Pennsylvania in the United States.
As major presentations, an oral presentation will be given on the next-morning residual effects of lemborexant from the results of three placebo-controlled, active comparator, randomized, double-blind clinical studies evaluating on-road driving performance as well as postural stability, and memory and attention performance directly after awakening.
Regarding perampanel, a total of 18 poster presentations will be given, including on the final analysis results from a Phase III clinical study (Study 311) in pediatric patients aged 4 to 12 years old with epilepsy, as well as on inpatient hospitalization risk in patients with epilepsy before and after perampanel treatment.
Eisai considers neurology a therapeutic area of focus, and strives to maximize the value of lemborexant and perampanel to further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, patients and their families.
About Lemborexant
Lemborexant is a novel investigational small molecule compound, discovered and developed by Eisai in-house scientists, that inhibits orexin signaling by binding competitively to both orexin receptor subtypes (orexin receptor 1 and 2). In individuals with normal daily sleep-wake rhythms, orexin signaling is believed to promote periods of wakefulness. In individuals with sleep-wake disorders, it is possible that orexin signaling that regulates wakefulness is not functioning normally, suggesting that inhibiting inappropriate orexin signaling may enable initiation and maintenance of sleep. Additionally, a Phase 2 clinical study of lemborexant in patients with irregular sleep-wake rhythm disorder (ISWRD) and mild to moderate Alzheimer's dementia is underway.
About Perampanel (generic name, product name: Fycompa)
Perampanel is a first-in-class AED discovered and developed by Eisai. With epileptic seizures being mediated by the neurotransmitter glutamate, the agent is a highly selective, noncompetitive AMPA receptor antagonist that reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at AMPA receptors on postsynaptic membranes. Perampanel is available in tablet form to be taken once daily orally at bedtime. In addition, an oral suspension formulation has been approved in the United States.
Perampanel is currently approved in more than 55 countries and territories, including the United States, Japan, in Europe and in Asia as adjunctive treatment for partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 12 years of age and older. An application seeking approval for use in the adjunctive treatment of partial-onset seizures is under review in China, which has been designated for Priority Review. In addition, Perampanel has been approved in more than 50 countries, including the United States, Japan, in Europe and in Asia for treatment as an adjunctive therapy for tonic-clonic seizures in patients with generalized epilepsy 12 years of age and older. In the United States, Perampanel is approved for monotherapy and adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) in patients with epilepsy 4 years of age and older. In Japan, a supplementary new drug application has been filed seeking approval of Perampanel for use as monotherapy for partial-onset seizures, treatment for partial-onset seizures in pediatric patients aged 4 years and older, as well as a fine granule formulation. In Europe, an application has been submitted seeking the additional approval of Perampanel for adjunctive use in the treatment of partial-onset seizures (with or without secondarily generalized seizures) or primarily generalized tonic-clonic seizures in pediatric patients with epilepsy.
Furthermore, Eisai is conducting a global Phase III clinical study (Study 338) for the agent in patients with epileptic seizures associated with Lennox-Gastaut syndrome.
Contact:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120
Topic: Press release summary
Source: Eisai
Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Eisai |
| Sept 12, 2025 12:20 HKT/SGT |
|
"New Answers to Dementia" Eisai Releases Concept Movie and New Content on Campaign Website for Dementia Month |
| Sept 8, 2025 16:49 HKT/SGT |
|
Eisai Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025 |
| Sept 4, 2025 09:56 HKT/SGT |
|
Eisai to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025 |
| Sept 3, 2025 10:32 HKT/SGT |
|
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status |
| Sept 1, 2025 12:44 HKT/SGT |
|
FDA Approves LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer's Disease |
| Aug 29, 2025 17:17 HKT/SGT |
|
Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma |
| Aug 25, 2025 18:30 HKT/SGT |
|
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI(R) (lecanemab) |
| Aug 18, 2025 08:11 HKT/SGT |
|
Eisai Launches In-House Developed Anti-Insomnia Drug DAYVIGO(R) (Lemborexant) in China |
| July 31, 2025 17:27 HKT/SGT |
|
Revenue of LEQEMBI(R) (Preliminary Basis) |
| July 31, 2025 08:30 HKT/SGT |
Early Alzheimer's Patients Continue to Benefit from Four Years of LEQEMBI(R) (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
|
| More news >> |
 |
|
|
|
